Zacks: Brokerages Expect Insulet Co. (PODD) Will Post Earnings of $0.07 Per Share

Wall Street brokerages expect Insulet Co. (NASDAQ:PODD) to post earnings of $0.07 per share for the current quarter, according to Zacks Investment Research. Nine analysts have issued estimates for Insulet’s earnings, with the highest EPS estimate coming in at $0.09 and the lowest estimate coming in at $0.03. Insulet reported earnings of ($0.12) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 158.3%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, February 20th.

On average, analysts expect that Insulet will report full year earnings of ($0.05) per share for the current year, with EPS estimates ranging from ($0.12) to ($0.02). For the next year, analysts expect that the business will report earnings of $0.39 per share, with EPS estimates ranging from $0.14 to $0.78. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Insulet.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 1st. The medical instruments supplier reported $0.03 EPS for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.01. The firm had revenue of $151.10 million for the quarter, compared to the consensus estimate of $148.82 million. Insulet had a negative net margin of 2.54% and a negative return on equity of 7.63%. The firm’s revenue was up 24.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.04) earnings per share.

PODD has been the subject of several research analyst reports. Oppenheimer set a $100.00 target price on shares of Insulet and gave the company a “hold” rating in a research note on Friday, November 2nd. BidaskClub cut shares of Insulet from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 25th. Zacks Investment Research upgraded shares of Insulet from a “hold” rating to a “buy” rating and set a $96.00 target price for the company in a research note on Tuesday, August 7th. Jefferies Financial Group reiterated a “buy” rating and set a $97.00 target price on shares of Insulet in a research note on Friday, August 3rd. Finally, Leerink Swann reiterated an “outperform” rating and set a $130.00 target price on shares of Insulet in a research note on Tuesday, September 11th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $101.20.

In other news, SVP Michael P. Spears sold 5,043 shares of the company’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $86.08, for a total value of $434,101.44. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Aiman Abdel-Malek sold 602 shares of the company’s stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $86.60, for a total transaction of $52,133.20. The disclosure for this sale can be found here. Insiders sold a total of 8,943 shares of company stock worth $803,215 in the last three months. Insiders own 3.60% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Putnam Investments LLC grew its holdings in shares of Insulet by 2.1% in the 2nd quarter. Putnam Investments LLC now owns 29,224 shares of the medical instruments supplier’s stock worth $2,505,000 after purchasing an additional 599 shares during the last quarter. Aperio Group LLC grew its holdings in shares of Insulet by 15.3% in the 2nd quarter. Aperio Group LLC now owns 4,976 shares of the medical instruments supplier’s stock worth $426,000 after purchasing an additional 660 shares during the last quarter. Granite Investment Partners LLC grew its holdings in shares of Insulet by 11.2% in the 3rd quarter. Granite Investment Partners LLC now owns 6,774 shares of the medical instruments supplier’s stock worth $718,000 after purchasing an additional 682 shares during the last quarter. Swiss National Bank grew its holdings in shares of Insulet by 1.1% in the 2nd quarter. Swiss National Bank now owns 102,200 shares of the medical instruments supplier’s stock worth $8,759,000 after purchasing an additional 1,100 shares during the last quarter. Finally, Tirschwell & Loewy Inc. grew its holdings in shares of Insulet by 0.4% in the 2nd quarter. Tirschwell & Loewy Inc. now owns 304,165 shares of the medical instruments supplier’s stock worth $26,067,000 after purchasing an additional 1,125 shares during the last quarter.

NASDAQ PODD traded down $3.81 during trading on Friday, reaching $87.60. The company’s stock had a trading volume of 536,402 shares, compared to its average volume of 684,941. The company has a quick ratio of 5.01, a current ratio of 4.58 and a debt-to-equity ratio of 2.95. Insulet has a 1-year low of $66.57 and a 1-year high of $108.90. The stock has a market capitalization of $5.33 billion, a PE ratio of -190.43 and a beta of 1.67.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

See Also: Google Finance Portfolio Workaround

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply